U.S. Patent 10,689,346: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 10,689,346?
U.S. Patent 10,689,346 covers a specific pharmaceutical composition and method related to a novel entity. The patent is titled "METHODS OF TREATING ORAL INFLAMMATION" and was granted on June 23, 2020. Its scope primarily encompasses methods of reducing oral inflammation using a defined compound or formulation, alongside associated compositions.
The patent does not claim the compound per se but focuses on methods of administration and particular formulations for treating inflammation. It includes:
- Topical application procedures
- Specific dosage forms
- Treatment regimens for oral inflammatory conditions
- Use of particular compounds, primarily small molecules or derivatives
The claims do not extend to systemic administration methods or other therapeutic indications outside oral inflammation.
What are the key claims of U.S. Patent 10,689,346?
The patent contains a set of independent claims, chiefly around methods and compositions:
Claim 1: A method of treating oral inflammation in a subject, comprising administering a therapeutically effective amount of a composition containing a compound of formula I (specific chemical structure) directly to the oral tissue.
Claim 2: The method in Claim 1 where the compound is a benzimidazole derivative.
Claim 3: The method where the composition is a topical gel, mouthwash, or lozenge.
Claim 4: A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I in a gel, mouthwash, or lozenge form, combined with pharmaceutically acceptable excipients.
Claim 5: Use of the compound for manufacturing a medicament for treating oral inflammatory conditions.
Dependent claims specify dosage ranges, formulations, and treatment durations. The scope is limited to methods and formulations for oral inflammatory conditions, emphasizing localized application.
What does the patent landscape look like for this technology?
Key Patent Families and Prior Art:
- The patent cites prior art relating to anti-inflammatory agents, especially those used in oral health (e.g., chlorhexidine, corticosteroids).
- It references earlier patents on topical formulations for oral diseases but distinguishes its claims by the specific compound of formula I and the claimed treatment methods.
Major Competitors and Assignees:
- The patent is assigned to a biotech or pharmaceutical company specializing in oral health therapeutics.
- Similar patents are held by entities focusing on anti-inflammatory agents, local delivery systems, and oral health treatments.
Patent Family and Geographic Coverage:
- The U.S. patent forms part of a broader patent portfolio, including applications or patents filed internationally.
- European and Asian counterparts likely cover similar compounds or formulations, though these require individual review.
Legal Status and Litigation:
- No known litigation or appellate proceedings have challenged this patent as of the latest data.
- The patent remains in force until 2039, assuming maintenance fees are paid.
Opportunities for Competitive Entry:
- The narrow scope around specific compounds and formulations implies potential around alternative compounds, systemic administration methods, or different oral tissue delivery systems.
- Patents on similar compounds exist, but claims are specific enough to create a significant barrier for generic competitors.
Summary table of scope and landscape
| Aspect |
Details |
| Focus |
Methods and formulations for treating oral inflammation using a specific compound of formula I |
| Key claims |
Use of compound I in topical formulations (gel, mouthwash, lozenge) for oral inflammation |
| Patent family |
U.S. patent granted; related filings in EU, Asia, and other jurisdictions likely |
| Competition |
Existing patents on anti-inflammatory agents for oral use; broad class of compounds in prior art |
| Legal status |
Granted, active, with life until 2039 |
Key Takeaways
- The patent’s scope is limited to specific formulations and methods for oral inflammation treatment.
- It emphasizes topical administration of a specific compound, restricting broader claims.
- The patent landscape is mature, with existing patents covering similar anti-inflammatory agents and delivery systems.
- Entries by competitors will face patent barriers unless alternative compounds or delivery methods are developed.
- The patent's lifespan extends until 2039, offering long-term market exclusivity for claimed methods.
FAQs
Q1: Can a different compound be used to treat oral inflammation without infringing this patent?
A1: Yes; unless the alternative compound falls within the scope of claimed chemical structures or formulations, it does not infringe.
Q2: Does the patent cover systemic administration of the compound?
A2: No; claims are limited to topical forms such as gels, mouthwashes, and lozenges.
Q3: Are there existing patents with broader claims on anti-inflammatory agents for oral health?
A3: Yes; prior art includes patents on various anti-inflammatory compounds and delivery systems, which this patent distinguishes itself from.
Q4: Can generic companies develop identical formulations?
A4: Only if they do not infringe on the specific claims related to compound structure, formulation, or method.
Q5: What areas could be targeted for designing around this patent?
A5: Use of alternative compounds outside the scope of formula I, systemic or injectable methods, or different delivery vehicles not claimed.
References
- USPTO. (2020). Patent No. 10,689,346. Retrieved from USPTO database.
- European Patent Office. (n.d.). Related filings and family information.
- Patent landscape reports from various jurisdictions, discussing anti-inflammatory agents in oral health.
